The stock of FireEye, Inc. (NASDAQ:FEYE) is a huge mover today! The stock increased 2.16% or $0.28 during the last trading session, reaching $13.26. About 3.12M shares traded. FireEye, Inc. (NASDAQ:FEYE) has declined 3.23% since August 14, 2018 and is downtrending. It has underperformed by 3.23% the S&P500. Some Historical FEYE News: 17/04/2018 – NSS Labs Announces 2018 Advanced Endpoint Protection Group Test Results; 15/03/2018 – There are no rules of engagement in cyberspace, says FireEye CEO Kevin Mandia, leaving countries that rely heavily on the internet, like the U.S., vulnerable to cyber attacks; 05/03/2018 FireEye Forms Golden Cross: Technicals; 02/05/2018 – FIREEYE 1Q REV. $199.1M, EST. $194.5M; 04/05/2018 – “Mad Money” host Jim Cramer hears from Kevin Mandia, the CEO of FireEye, about the risks that cryptocurrencies pose to cybersecurity; 21/05/2018 – FIREEYE, REPORTS $525.0M CONV NOTES OFFERING; 02/05/2018 – FireEye Sees 2Q Adj Loss/Shr 3c-Adj EPS $0.00; 17/04/2018 – FireEye Introduces New Email Security Capabilities Driven By Deep Learning; 16/03/2018 – FEYE: FireEye in focus as Cisco, Symantec watch turnaround [MORE; 04/05/2018 – Bitcoin’s ‘been a problem for us,’ says CEO of top cybersecurity firm FireEyeThe move comes after 9 months positive chart setup for the $2.85B company. It was reported on Aug, 14 by Barchart.com. We have $14.45 PT which if reached, will make NASDAQ:FEYE worth $256.32 million more.
Chemocentryx Inc (NASDAQ:CCXI) had an increase of 52.27% in short interest. CCXI’s SI was 3.21 million shares in August as released by FINRA. Its up 52.27% from 2.11M shares previously. With 523,500 avg volume, 6 days are for Chemocentryx Inc (NASDAQ:CCXI)’s short sellers to cover CCXI’s short positions. The SI to Chemocentryx Inc’s float is 10.5%. The stock increased 0.71% or $0.05 during the last trading session, reaching $7.07. About 78,714 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has declined 28.17% since August 14, 2018 and is downtrending. It has underperformed by 28.17% the S&P500. Some Historical CCXI News: 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 ChemoCentryx 4Q EPS 80c; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80
Among 2 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 4 analyst reports since March 12, 2019 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $23 target in Tuesday, March 12 report. The rating was upgraded by FBR Capital on Wednesday, March 27 to “Buy”.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx (CCXI) Reports Q2 Loss, Lags Revenue Estimates – Nasdaq” on August 05, 2019, also Seekingalpha.com with their article: “ChemoCentryx down 16% after Q2 revenue miss – Seeking Alpha” published on August 06, 2019, Finance.Yahoo.com published: “ChemoCentryx Inc (CCXI) Q2 2019 Earnings Call Transcript – Yahoo Finance” on August 08, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Nasdaq.com and their article: “ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019 – Nasdaq” published on July 31, 2019 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx, Inc. 2019 Q2 – Results – Earnings Call Slides – Seeking Alpha” with publication date: August 06, 2019.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $411.83 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.
Investors sentiment increased to 1.44 in 2019 Q1. Its up 0.51, from 0.93 in 2018Q4. It improved, as 12 investors sold ChemoCentryx, Inc. shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Jacobs Levy Equity Management invested in 0.01% or 51,190 shares. Jpmorgan Chase reported 5,481 shares. Acadian Asset Llc owns 775,123 shares. Fernwood Inv Lc invested in 10,000 shares. Federated Investors Incorporated Pa stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Pub Employees Retirement Systems Of Ohio holds 0.01% or 99,284 shares. 6,829 are owned by Citigroup Inc. Wasatch Advsrs has invested 0.37% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Moreover, Clarivest Asset Mgmt Limited has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). 4,696 are owned by Bnp Paribas Arbitrage. Charles Schwab Mngmt holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 49,177 shares. Spark Inv Mgmt Ltd Liability Company owns 184,500 shares. The Ohio-based Strs Ohio has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Gsa Capital Llp, a United Kingdom-based fund reported 91,400 shares. New York State Common Retirement Fund has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI).
More notable recent FireEye, Inc. (NASDAQ:FEYE) news were published by: Finance.Yahoo.com which released: “What Is FireEye, Inc.’s (NASDAQ:FEYE) Share Price Doing? – Yahoo Finance” on July 29, 2019, also Seekingalpha.com with their article: “FireEye Continues To Sink On Weak Fundamentals – Seeking Alpha” published on August 06, 2019, Nasdaq.com published: “FireEye (FEYE) to Report Q2 Earnings: What’s in the Offing? – Nasdaq” on July 24, 2019. More interesting news about FireEye, Inc. (NASDAQ:FEYE) were released by: Nasdaq.com and their article: “FireEye (FEYE) Reports Q2 Loss, Tops Revenue Estimates – Nasdaq” published on July 30, 2019 as well as Seekingalpha.com‘s news article titled: “Cybersecurity names move after CHKP earnings – Seeking Alpha” with publication date: July 24, 2019.
Investors sentiment decreased to 1.04 in 2019 Q1. Its down 0.26, from 1.3 in 2018Q4. It dived, as 27 investors sold FireEye, Inc. shares while 83 reduced holdings. 32 funds opened positions while 82 raised stakes. 154.37 million shares or 10.41% more from 139.82 million shares in 2018Q4 were reported. Jefferies Grp Limited Liability Company holds 48,504 shares. Broadview Advisors Limited Liability Company holds 2.47% or 540,050 shares in its portfolio. Moreover, Trellus Co has 3.36% invested in FireEye, Inc. (NASDAQ:FEYE) for 105,096 shares. Pier Capital Ltd Llc holds 1.11% of its portfolio in FireEye, Inc. (NASDAQ:FEYE) for 426,613 shares. Moreover, Swiss National Bank & Trust has 0.01% invested in FireEye, Inc. (NASDAQ:FEYE) for 341,100 shares. Paw Cap Corporation accumulated 145,000 shares or 2.41% of the stock. Wesbanco Bancorporation holds 94,168 shares or 0.08% of its portfolio. Credit Suisse Ag has invested 0.02% in FireEye, Inc. (NASDAQ:FEYE). Private Wealth Lc has invested 0.18% in FireEye, Inc. (NASDAQ:FEYE). Commerzbank Aktiengesellschaft Fi reported 0.01% in FireEye, Inc. (NASDAQ:FEYE). The New York-based New York State Common Retirement Fund has invested 0.01% in FireEye, Inc. (NASDAQ:FEYE). Lpl Financial Limited Liability Company holds 0% or 38,223 shares in its portfolio. Signaturefd Limited Liability Company reported 500 shares or 0% of all its holdings. Stone Ridge Asset Mngmt Ltd Liability Corp invested 0.09% in FireEye, Inc. (NASDAQ:FEYE). Eaton Vance Mgmt has 111,351 shares.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.